SHTDF — Sinopharm Co Income Statement
0.000.00%
Last trade - 00:00
- $6.87bn
- $21.71bn
- CNY596.57bn
- 85
- 99
- 17
- 74
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 425,273 | 456,415 | 521,051 | 552,148 | 596,570 |
Cost of Revenue | |||||
Gross Profit | 37,531 | 40,323 | 44,051 | 47,434 | 48,512 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 409,250 | 438,788 | 501,949 | 531,605 | 576,367 |
Operating Profit | 16,023 | 17,626 | 19,103 | 20,543 | 20,203 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13,760 | 15,598 | 17,003 | 18,564 | 19,512 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10,620 | 12,097 | 13,065 | 14,345 | 15,010 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6,253 | 7,187 | 7,759 | 8,526 | 9,054 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6,251 | 7,187 | 7,759 | 8,526 | 9,054 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.13 | 2.33 | 2.62 | 2.74 | 2.79 |
Dividends per Share |